Treatment of Challenging Mantle Cell Lymphoma Cases

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Ariana Pelosci

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Andrew M. Evens, DO, MBA, MSc

November 18th 2024

Pinpointing Ways to Overcome Challenges in MZL

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

ONCOLOGY Staff

Loncastuximab Tesirine Elicits Robust Responses in R/R Follicular Lymphoma

As MZL is such a rare subtype of lymphoma, it can be hard to find or begin trials geared specifically toward this population.

Roman Fabbricatore

February 14th 2025

Study Finds Recent Falls, Inability to Balance on Left Leg Indicate OS Decrease in NHL

The toxicity profile of loncastuximab tesirine plus rituximab was consistent with prior clinical trials assessing each agent as monotherapy.

Related Content

Tim Cortese

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Ariana Pelosci

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Andrew M. Evens, DO, MBA, MSc

November 18th 2024

Pinpointing Ways to Overcome Challenges in MZL

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

ONCOLOGY Staff

Loncastuximab Tesirine Elicits Robust Responses in R/R Follicular Lymphoma

As MZL is such a rare subtype of lymphoma, it can be hard to find or begin trials geared specifically toward this population.

Roman Fabbricatore

February 14th 2025